Fundraising Fox
/Companies
Sign in

Nuvation Bio

NYSE: NUVB

New York, US · Founded 2018 · Incorporated in Delaware · 5 known investors

Find your way into Nuvation Bio

Each arrow is one introduction. Sign up to fill in the first one.

411 people can intro you to Stephen

Ask Christopher Claeboe to introduce you to Stephen Dang

You →Christopher · together at ChemoCentryx →Stephen

303 people can intro you to Philippe

Ask Jamie Chen to introduce you to Philippe Sauvage

You →Jamie · together at AP-HP, Assistance Publique - Hôpitaux de Paris →Philippe

113 people can intro you to Kerry

Ask Sam Okafor to introduce you to Kerry Wentworth

You →Sam · together at Genelabs Technologies →Kerry

Sign up to find every way you can get introduced to Nuvation Bio

  • Your email: who you already know at Nuvation Bio, and who your contacts know
  • 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Nuvation Bio team
  • Your LinkedIn: the connections who can make the intro for you

We rank every route by how warm it is, so you raise on warm intros instead of cold emails.

Sign up with GoogleAlready have an account? Log in

Nuvation Bio is a global oncology company that develops novel cancer therapies through its own drug discovery programs and business development, serving cancer patients. Founded in 2018, it became a commercial-stage company in 2025.

BiotechHealthtech

Founders & leadership

Nuvation Bio was founded in 2018 by David Hung.

DHDavid Hung
David HungFounderDavid Hung founded Nuvation Bio in 2018 after founding Medivation in 2003, where he identified and led development of multiple oncology programs including the prostate cancer drug enzalutamide before Medivation's acquisition by Pfizer for $14.3B in 2016. Earlier in his career, he served as CEO of Pro•Duct Health, a medical device startup he founded, and trained as a hematologist-oncologist.
DHDavid Hanley
David HanleyChief Technical Operations Officer
GHGary Hattersley
Gary HattersleyChief Scientific Officer
SMStacy Markel
Stacy MarkelChief People Officer
PSPhilippe Sauvage
Philippe SauvageChief Financial OfficerHe brings finance, marketing, and operations experience across public and private sector roles in the US, Europe, and Asia, with expertise in systems transformation including CRM, SAP implementations, and M&A.
CSColleen Sjogren
Colleen SjogrenChief Commercial OfficerShe has experience designing and building out commercial organizations and launching therapies in the oncology space.
KW
Kerry WentworthChief Regulatory OfficerHe brings expertise in drug development, US and international regulatory affairs, and biologic and drug manufacturing.
SDStephen Dang
Stephen DangChief Legal OfficerHe brings experience in pharmaceutical and biotech legal matters across drug discovery, development, commercialization, and generic entry.

Board

MD
Michelle DoigBoard Of Directors2019–2021Partner at Omega Funds
CNClaudio Nessi
Claudio NessiBoard directorManaging Director at Omega Funds
KB
Kim BlickenstaffBoard director
KE
Kathryn E. FalbergBoard director

Investors · 5

Decheng Capitallisted by Decheng CapitalMenlo Park

How we know: Decheng Capital's portfolio page · Not right? Tell us

EcoR1 Capitallisted by EcoR1 CapitalSan Francisco
Vertex Ventures Chinalisted by Vertex Ventures ChinaSingapore

How we know: Vertex Ventures China's portfolio page · Not right? Tell us

Omega FundsinferredBostonvia Michelle Doig · board

How we know: board seat on SEC Form D · Not right? Tell us

Reported raises · per SEC filings

Form D private placements

$275.3M disclosed across 1 of 2 rounds · 2019–2026

▶$275.3MraisedOct 2020 · 57 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • David Hung, M.D.Executive Officer, Director
  • Kim BlickenstaffDirector
  • Michelle DoigDirector
  • Kathryn E. FalbergDirector
  • Claudio NessiDirector
  • W. Anthony VernonDirector
  • Daniel WelchDirector
  • Robert BazemoreDirector
Offering amount
$275.3M
Amount sold
$275.3M
First sale
Jun 2019
Incorporated
Corporation, Delaware, 2018
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Frequently asked questions

What does Nuvation Bio do?
Nuvation Bio is a global oncology company that develops novel cancer therapies through its own drug discovery programs and business development, serving cancer patients. Founded in 2018, it became a commercial-stage company in 2025.
Who founded Nuvation Bio?
Nuvation Bio was founded by David Hung in 2018.
Who are Nuvation Bio's investors?
Nuvation Bio's investors include Aisling Capital, Decheng Capital, EcoR1 Capital, Vertex Ventures China, Omega Funds.
How much funding has Nuvation Bio raised?
Nuvation Bio has disclosed $275.3M raised across 1 of its 2 known rounds.
Where is Nuvation Bio headquartered?
Nuvation Bio is headquartered in New York, US.